Invion Ltd
ASX:IVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Invion Ltd
Net Income (Common)
Invion Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Invion Ltd
ASX:IVX
|
Net Income (Common)
-AU$8.8m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
4%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Net Income (Common)
-AU$30.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Income (Common)
-AU$93.8m
|
CAGR 3-Years
31%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Income (Common)
AU$30.4m
|
CAGR 3-Years
449%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Net Income (Common)
-AU$64.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Net Income (Common)
AU$10.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
Invion Ltd
Glance View
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatments for market opportunities in a variety of cancer indications, chronic inflammatory, and autoimmune diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is focused on the development of Photosoft technology for the treatment of a range of cancers. The firm is conducting various clinical trials for the development of its Photosoft technology. Its Photo Dynamic Therapy (PDT) is a treatment that optimizes the use of non-toxic photosensitizers and visible light to kill cancer and stimulate the immune system. The firm aims to develop photosensitizer, IVX-PDT, that improves the treatment of skin cancers and hard-to-treat solid cancers, such as those present in ovarian, prostate and lungs. Epitech Dermal Science Pty Ltd is the wholly owned subsidiary of the Company.
See Also
What is Invion Ltd's Net Income (Common)?
Net Income (Common)
-8.8m
AUD
Based on the financial report for Jun 30, 2025, Invion Ltd's Net Income (Common) amounts to -8.8m AUD.
What is Invion Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
4%
Over the last year, the Net Income (Common) growth was -57%. The average annual Net Income (Common) growth rates for Invion Ltd have been -58% over the past three years , -56% over the past five years , and 4% over the past ten years .
